A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Details
Age
Adult
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Emily Forbes
Study ID
Protocol Number: 23-0328
More information available at ClinicalTrials.gov: NCT05819359
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers